Daniel M. Halperin, MD, is the new vice chair for clinical affairs in Emory University School of Medicine's Department of Hematology and Medical Oncology.
Daniel M. Halperin, MD, a renowned clinical trialist and board-certified medical oncologist specializing in neuroendocrine tumors (NETs), joins Winship Cancer Institute of Emory University as vice chair for clinical affairs and associate professor in Emory University School of Medicine's Department of Hematology and Medical Oncology on Sept. 1.
"Dr. Halperin is an exceptionally talented oncologist and clinical investigator, and we are so pleased to welcome him to the department," said Sagar Lonial, MD, Winship's chief medical officer, chair of the Emory Department of Hematology and Medical Oncology, and the Anne and Bernard Gray Family Chair in Cancer. "He joins an expanding and outstanding team of gastrointestinal cancer specialists at Winship, and we look forward to adding his leadership and expertise in the area of neuroendocrine tumor research and clinical care to the team."
Halperin comes from The University of Texas MD Anderson Cancer Center, where he was an instrumental clinical and research leader in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine. He was the clinical medical director for MD Anderson's Gastrointestinal Center as it transformed into a multicampus service line, and director of clinical research operations in the Department of Gastrointestinal Medical Oncology during a period of dramatic reduction of trial activation timelines. He also served as chair of the NET Multidisciplinary Conference (Tumor Board) at MD Anderson and represented the institution on the Neuroendocrine and Adrenal Tumor guideline committee of the National Comprehensive Cancer Network (NCCN). He currently serves on the Board of Scientific Advisors of the NET Research Foundation, the Scientific Advisory Committee of the Healing NET Foundation and the Board of Directors and Symposium Committee of the North American Neuroendocrine Tumor Society.
As a clinical investigator, Halperin is dedicated to providing world-class clinical care and developing novel therapies for patients with neuroendocrine tumors (NETs), which are tumors that develop from a diffuse network of neuroendocrine cells that make and release hormones into the bloodstream to control essential bodily functions. He has played a leading role in clinical trials of immunotherapy and radioligands for patients with NETs. He also collaborates with laboratory and population scientists to deepen our understanding of the molecular basis and clinical presentation of neuroendocrine tumors.
In his new role as vice chair of clinical affairs in the Department of Hematology and Medical Oncology, Halperin will work with the department chair and other leaders to plan, communicate and execute Winship strategies and organizational goals in the clinical arena, and to support and direct the performance of physician faculty members in the department. He will also, among other responsibilities, work with peers and health system leaders in Emory Healthcare and affiliates to optimize care delivery and clinical program growth and development.
“Winship is an amazing place where constant innovation and patient centricity are intrinsic to its mission to find cures and inspire hope,” says Halperin. “I feel so privileged to join this exceptional organization and contribute to the continued growth of both the neuroendocrine program and the broader oncology service.”
A graduate of Massachusetts Institute of Technology, Halperin completed his medical degree at Weill Cornell Medical College in New York, his internal medicine residency at Brigham and Women's Hospital in Boston and his medical oncology training at MD Anderson in Houston.